Malignant Neoplasm of Unknown Primary

NIH-3T3 cells with the FGFR2 W290C extracellular domain mutation demonstrated an increase in colony formation in an anchorage independent growth assay, which was lost with the introduction of AP24534,… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

FGFR3 G691R mutations were found in ~5.5% of lung adenocarcinoma patients using NGS and mass-spectrometry. The mutation was further found to transform NIH-3T3 cells and form tumors upon xenotransplant… (full text at CIViC)

PMID 27998968 · Chandrani et al., 2017 · Open in CIViC

The study analysed the expression of the two splice variants of FGFR3 (FGFR3-IIIb and FGFR3-IIIc/FGFR3-IIIc-KD) in two pancreatic ductal adenocarcinoma cell lines (Capan-2 and BxPC-3). The FGFR3-IIIc-… (full text at CIViC)

PMID 23902722 · Lafitte et al., 2013 · Open in CIViC

NIH-3T3 cells with the FGFR3 R248C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by treatm… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

Expression of FGFR3 carrying the p.Arg248Cys variant in HEK293 cells resulted in increased phospho-ERK, indicating activation of the MAP Kinase pathway. Expression of FGFR3 p.Arg248Cys in a human kera… (full text at CIViC)

PMID 24626198 · Duperret et al., 2014 · Open in CIViC

NIH-3T3 cells with the FGFR3 S249C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by the tr… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In this study, 363 lung adenocarcinoma tumors of Indian origin were analyzed using targeted next-generation sequencing and mass spectrometry genotyping, and FGFR3 mutations were identified in 20 tumor… (full text at CIViC)

PMID 27998968 · Chandrani et al., 2017 · Open in CIViC

In this report, Mizukami et al. explored major FGFR1, FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n = 74 and 114, respectively) using a most comprehensive next-generation sequencing … (full text at CIViC)

PMID 27771611 · Mizukami et al., 2017 · Open in CIViC

Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR4 G665E achieved a partial response. The same tumor also harbored FGFR2 M538I, pr… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

In the open‑label phase II AVATAR trial (NCT01130519), patients with HLRCC‑associated papillary RCC harboring germline FH pathogenic variants (n = 43) received erlotinib plus bevacizumab, with ORR as … (full text at CIViC)

PMID 40532152 · Srinivasan et al., 2025 · Open in CIViC

In the open‑label phase II AVATAR trial (NCT01130519), patients with sporadic papillary RCC (n = 40) received erlotinib plus bevacizumab, with ORR as the primary endpoint. They demonstrated a lower OR… (full text at CIViC)

PMID 40532152 · Srinivasan et al., 2025 · Open in CIViC

A case study showed that the mTOR inhibitor everolimus exhibited a relatively long-term effect in a patient with renal cell carcinoma and a FLCN germline mutation (c. 1285dupC, likely loss of function… (full text at CIViC)

PMID 23995526 · Nakamura et al., 2013 · Open in CIViC

In a patient with Birt-Hogg-Dubé syndrome-associated papillary renal cell carcinoma use of everolimus as sixth-line systematic treatment exhibited a relatively long-term effect as compared with the pr… (full text at CIViC)

PMID 23995526 · Nakamura et al., 2013 · Open in CIViC

In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia. 95% confi… (full text at CIViC)

PMID 19667267 · van Erp et al., 2009 · Open in CIViC

A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma. Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAA… (full text at CIViC)

PMID 27022066 · Jones et al., 2016 · Open in CIViC

From October 2015 to April 2019, 103 HCC patients scheduled to receive chemoembolization were screened. Of them, 84 met inclusion criteria and were assigned to TT (TACE) (n = 25), Non-TT (TACE) (n = 3… (full text at CIViC)

PMID 34982369 · Chen et al., 2022 · Open in CIViC

128 patients with oral squamous cell carcinoma (OSCC) and 145 normal control subjects were evaluated for the concentration of GAS6 in their plasma serum. OSCC patients were found to be associated with… (full text at CIViC)

PMID 26207647 · Jiang et al., 2015 · Open in CIViC

Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.

PMID 22541434 · Kumar et al., 2012 · Open in CIViC

In this study, Kaplan-Meier curves for tumor progression, development of metastasis, and tumor-related death showed a significant association of the T393C polymorphism with outcome (5-year cancer-spec… (full text at CIViC)

PMID 16467086 · Frey et al., 2006 · Open in CIViC

This paper details a prospective single-arm personalized cancer therapy study with n = 16 patients. The disease type was peritoneal mucinous carcinomatosis, predominantly of appendiceal origin. Palboc… (full text at CIViC)

PMID 39413348 · Weitz et al., 2025 · Open in CIViC

Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.… (full text at CIViC)

PMID 27154293 · Pietrantonio et al., 2016 · Open in CIViC

A 79 year old patient with prior 5-year history of Graves' disease presented with follicular thyroid carcinoma. Two mutations NRAS p.Q61K and GNAS p.R201H were detected. The thyroid cancer manifested … (full text at CIViC)

PMID 26788326 · Lu et al., 2016 · Open in CIViC

This case study reports a 78 year old patient with pancreatic adenocarcinoma harboring a GP2::NTRK1 gene fusion characterized by an in-frame rearrangement involving exon 2 of GP2 and exon 8 of NTRK1. … (full text at CIViC)

PMID 42412359 · Tazuma et al., 2026 · Open in CIViC

In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC)

PMID 26883990 · Koyama et al., 2016 · Open in CIViC

In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC)

PMID 26883990 · Koyama et al., 2016 · Open in CIViC

In this phase Ib study (NCT01543763), the histone deacetylase (HDAC) inhibitor abexinostat was used in combination with the multi-tyrosine kinase inhibitor pazopanib to evaluate the effect of abexinos… (full text at CIViC)

PMID 28221861 · Aggarwal et al., 2017 · Open in CIViC

The HIF1A rs2057482 SNP was genotyped in 410 pancreatic ductal adenocarcinoma cases and 490 healthy controls. The CC genotype was significantly correlated with PDAC risk (OR = 1.719, 95% CI: 1.293-2.2… (full text at CIViC)

PMID 26872370 · Wang et al., 2016 · Open in CIViC

Immunohistochemical staining for HIF1A was performed on tumor samples from 65 patients that received pazopanib as part of VEG102616, of which 17 were classified as low expression and 48 were classifie… (full text at CIViC)

PMID 23881929 · Choueiri et al., 2013 · Open in CIViC

In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% v… (full text at CIViC)

PMID 26309414 · Zheng et al., 2015 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

In this preclinical study, cell lines with constitutively-active G12V mutant found that forced overexpression of HRAS G12V caused a reduced susceptibility to PI3K inhibitor BYL719 in comparison to wil… (full text at CIViC)

PMID 30115483 · Ruicci et al., 2018 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

In a phase II HNSCC trial, an objective response rate of 55% was seen in HRAS-mutant patients (11 of 20) treated with the farnesyltransferase inhibitor tipifarnib with a PFS of 5.6 months and an OS of… (full text at CIViC)

PMID 33750196 · Ho et al., 2021 · Open in CIViC

Follicular thyroid cancers harboring RAS mutations have limited aggressiveness in the absence of TERT mutations. 2/2 follicular thyroid cancer patients with co-mutations in NRAS (10 Q61R and 1 Q61K) o… (full text at CIViC)

PMID 25448848 · Muzza et al., 2015 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine.

PMID 22004109 · Schäfer et al., 2012 · Open in CIViC

HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear e… (full text at CIViC)

PMID 26943774 · Kimura et al., 2016 · Open in CIViC

49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+… (full text at CIViC)

PMID 26943774 · Kimura et al., 2016 · Open in CIViC

A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed mol… (full text at CIViC)

PMID 27466707 · Brody et al., 2018 · Open in CIViC

In pancreatic cancer patients, ganitumab was associated with improved OS compared with placebo. The effect of ganitumab on improved OS was stronger for patients with higher levels of IGF-2. As Figur… (full text at CIViC)

PMID 23741071 · McCaffery et al., 2013 · Open in CIViC

JAK1 mutations were identified by sequencing 60 HCC PDX tumour models. There mutations were then functionally characterized. HEK293FT cells were transfected with JAK1 WT or mutants (N451S, E483D, S703… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC